According to a new report published by Introspective Market Research, titled, Personalized Genomics Market by Test Type, Application, and End User, The Global Personalized Genomics Market Size Was Valued at USD 9.25 Billion in 2023 and is Projected to Reach USD 27.90 Billion by 2032, Growing at a CAGR of 17.19%.The global personalized genomics market is gaining remarkable traction as advancements in sequencing technologies and bioinformatics empower individuals to unlock insights from their unique genetic makeup. Personalized genomics refers to the use of genomic information to tailor healthcare, lifestyle, and wellness solutions, offering consumers valuable knowledge about disease risks, drug response, ancestry, and overall health management.
This market is rapidly expanding due to rising consumer awareness of preventive healthcare, falling sequencing costs, and the integration of artificial intelligence in data interpretation. Personalized genomics provides advantages over traditional diagnostic tools by enabling precise, data-driven decision-making in clinical and consumer health. Applications extend from oncology and pharmacogenomics to nutrition, fitness, and reproductive health, making it a transformative tool in both healthcare and consumer markets worldwide.
The Personalized Genomics Market is segmented into Test Type, Application, and End User.
-
By Test Type, the market is categorized into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others.
-
By Application, the market is categorized into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others.
-
By End User, the market is categorized into Hospitals & Clinics, Research Organizations, and Direct-to-Consumer.
A major growth driver for the personalized genomics market is the declining cost of sequencing technologies. Next-generation sequencing (NGS) has revolutionized genomics by reducing the time and expense required to decode the human genome. Affordable genomic testing kits are now accessible to a wider consumer base, allowing individuals to obtain insights into their genetic predispositions and health risks. This democratization of genomics is driving adoption not only in clinical settings but also in consumer markets, where people are increasingly using DNA-based insights to guide lifestyle, nutrition, and fitness decisions.
One of the most promising opportunities for the personalized genomics market lies in its integration with digital health platforms and artificial intelligence. AI-powered genomic interpretation tools are enabling healthcare providers to deliver highly precise treatment recommendations, while consumer applications leverage mobile apps to provide lifestyle guidance based on genetic data. This convergence of genomics with digital health ecosystems opens new avenues for personalized medicine, preventive healthcare, and consumer wellness solutions. As adoption increases, companies focusing on interoperability, secure data sharing, and real-time genetic insights stand to benefit significantly.
Personalized Genomics Market, Segmentation
The Personalized Genomics Market is segmented on the basis of Test Type, Application, and End User.
Test Type
The Test Type segment is further classified into Whole Genome Sequencing, Whole Exome Sequencing, Targeted Gene Sequencing, and Others. Among these, the Whole Genome Sequencing sub-segment accounted for the highest market share in 2023. Its dominance is attributed to the comprehensive data it provides, which supports applications in disease risk analysis, pharmacogenomics, and ancestry testing. Falling sequencing costs and increasing adoption in both research and consumer applications are fueling the growth of this segment.
Application
The Application segment is further classified into Oncology, Rare Diseases, Pharmacogenomics, Ancestry & Lifestyle, and Others. Among these, the Oncology sub-segment accounted for the highest market share in 2023. Personalized genomics in oncology enables clinicians to identify genetic mutations driving tumor growth and tailor treatment regimens to individual patients. The rise of precision medicine, combined with increasing cancer prevalence, is strengthening the demand for genomic testing in cancer care worldwide.
Some of The Leading/Active Market Players Are-
- Illumina, Inc. (USA)
- Thermo Fisher Scientific Inc. (USA)
- F. Hoffmann-La Roche AG (Switzerland)
- BGI Genomics Co., Ltd. (China)
- 23andMe, Inc. (USA)
- Myriad Genetics, Inc. (USA)
- Gene by Gene, Ltd. (USA)
- Color Health, Inc. (USA)
- Dante Labs (Italy)
- QIAGEN N.V. (Netherlands/Germany)
- Nebula Genomics (USA)
- Veritas Genetics (USA)
- Mapmygenome India Ltd. (India)
- Oxford Nanopore Technologies plc (UK)
- Invitae Corporation (USA)
- and other active players.
Key Industry Developments
- In May 2024, 23andMe launched a new wellness-focused DNA testing service aimed at offering customers insights into nutrition, sleep patterns, and fitness performance.
The initiative is expected to strengthen the company’s presence in the direct-to-consumer genomics space, expanding its customer base beyond traditional ancestry testing. - In October 2024, Illumina announced a partnership with major healthcare providers to integrate genomic testing into routine cancer care.
This collaboration will accelerate the adoption of personalized genomics in oncology, making precision medicine accessible to a broader population and advancing cancer treatment outcomes.
Key Findings of the Study
- Whole Genome Sequencing dominated the test type segment in 2023.
- Oncology remained the leading application area.
- North America led the market due to strong healthcare infrastructure and adoption of consumer genomics.
- Declining sequencing costs and AI-powered tools are major growth drivers.
- Integration with digital health platforms offers strong future opportunities.
